Purple Biotech (PPBT)
(Delayed Data from NSDQ)
$5.88 USD
+0.12 (1.99%)
Updated Oct 2, 2024 03:58 PM ET
After-Market: $5.88 0.00 (0.00%) 5:48 PM ET
2-Buy of 5 2
D Value C Growth A Momentum C VGM
Brokerage Reports
0 items in cart
Purple Biotech Ltd. Sponsored ADR [PPBT]
Reports for Purchase
Showing records 1 - 17 ( 17 total )
Company: Purple Biotech Ltd. Sponsored ADR
Industry: Medical - Drugs
2Q24 Recap: Additional Data From CM24 Phase 2 Study Expected Throughout 2H24
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: Purple Biotech Ltd. Sponsored ADR
Industry: Medical - Drugs
Positive PDAC Interim Data Noted for Randomized CM24 Phase 2 Trial Though More Patients Likely Needed
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: Purple Biotech Ltd. Sponsored ADR
Industry: Medical - Drugs
1Q24 Recap: CM24 Interim Data To Be Presented at ASCO; Topline Data Is Expected by 4Q24
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: Purple Biotech Ltd. Sponsored ADR
Industry: Medical - Drugs
Initial Positive Commentary Provided on Interim Data; Full Interim Results Expected at ASCO in June
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: Purple Biotech Ltd. Sponsored ADR
Industry: Medical - Drugs
4Q23 Recap: CM24 Phase 2 Interim Data and NT219 Phase 2 Initiation Expected 1H24
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: Purple Biotech Ltd. Sponsored ADR
Industry: Medical - Drugs
NT219 Dose Escalation Data Presented at ESMO TAT Show Encouraging Activity
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: Purple Biotech Ltd. Sponsored ADR
Industry: Medical - Drugs
NT219 to Advance Into Phase 2 With 100 mg/kg Dose For Treatment of SCCHN
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: Purple Biotech Ltd. Sponsored ADR
Industry: Medical - Drugs
3Q23 Recap: CM24 Interim Data Expected in 1H24; NT219 Early Efficacy Data Are Encouraging
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: Purple Biotech Ltd. Sponsored ADR
Industry: Medical - Drugs
2Q23 Recap: Timelines Remain on Track With Data Updates Expected in 2H23
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: Purple Biotech Ltd. Sponsored ADR
Industry: Medical - Drugs
1Q23 Recap: NT219 and CM24 Studies to Have Data Updates in 2023
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: Purple Biotech Ltd. Sponsored ADR
Industry: Medical - Drugs
4Q22 Take: Pipeline Progress Continues With Data Updates For CM24 and NT219 Expected in 2023
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: Purple Biotech Ltd. Sponsored ADR
Industry: Medical - Drugs
Noteworthy Discussion Points From Our Meetings at
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: Purple Biotech Ltd. Sponsored ADR
Industry: Medical - Drugs
3Q22 Take: Catalysts Across the Pipeline Expected Throughout 2023
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: Purple Biotech Ltd. Sponsored ADR
Industry: Medical - Drugs
First-in-Class Assets for Difficult to Treat Solid Tumors; Initiating at Buy and $7 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BODNAR E
Company: Purple Biotech Ltd. Sponsored ADR
Industry: Medical - Drugs
Company: Purple Biotech Ltd. Sponsored ADR
Industry: Medical - Drugs
Company: Purple Biotech Ltd. Sponsored ADR
Industry: Medical - Drugs
Name Change to Purple Biotech Ltd.; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
|